Clinical Trial Update: Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating temsirolimus with or without cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma after prior t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• Torisel (Temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-06